MyFinsight
Home
Blog
About
AVADEL PHARMACEUTICALS PLC (AVDL)
AVADEL PHARMACEUTICALS PLC (AVDL)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
$22,196K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Acquired in-process research & d...
Proceeds from sales of marketabl...
Share-based compensation expense
Others
Negative Cash Flow Breakdown
Upfront license payment for acqu...
Purchases of marketable securiti...
Accrued expenses
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-09-30
2025-06-30
Net income (loss)
20
4,745
Depreciation and amortization
1,115
1,893
Share-based compensation expense
4,919
9,510
Acquired in-process research & development expense
20,000
-
Other adjustments
-262
-786
Accounts receivable
1,813
6,534
Inventories
681
3,361
Prepaid expenses and other current assets
-842
2,404
Accounts payable & other current liabilities
2,289
2,778
Accrued expenses
-3,572
2,077
Other assets and liabilities
652
3,453
Net cash provided by (used in) operating activities
22,205
4,465
Purchases of property and equipment
9
181
Proceeds from sales of marketable securities
11,800
45,938
Purchases of marketable securities
5,224
41,694
Upfront license payment for acquired in-process research & development
15,000
-
Net cash (used in) provided by investing activities
-8,433
4,063
Proceeds from issuance of shares off the at-the-market offering program
0
0
Proceeds from stock option exercises and employee share purchase plan
2,507
1,672
Net cash provided by financing activities
2,507
1,672
Effect of foreign currency exchange rate changes on cash and cash equivalents
132
1,831
Net change in cash and cash equivalents
16,411
12,031
Cash and cash equivalents at beginning of period
51,371
-
Cash and cash equivalents at end of period
79,813
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Acquired in-process
research & development...
$20,000K
Share-based compensation
expense
$4,919K
Proceeds from stock
option exercises and...
$2,507K
Accounts payable & other
current liabilities
$2,289K
Depreciation and
amortization
$1,115K
Prepaid expenses and
other current assets
-$842K
Net income (loss)
$20K
Net cash provided by
(used in) operating...
$22,205K
Net cash provided by
financing activities
$2,507K
Effect of foreign
currency exchange rate...
$132K
Canceled cashflow
$6,980K
Net change in cash
and cash...
$16,411K
Canceled cashflow
$8,433K
Accrued expenses
-$3,572K
Accounts receivable
$1,813K
Inventories
$681K
Other assets and
liabilities
$652K
Other adjustments
-$262K
Proceeds from sales of
marketable securities
$11,800K
Net cash (used in)
provided by investing...
-$8,433K
Canceled cashflow
$11,800K
Upfront license payment
for acquired...
$15,000K
Purchases of marketable
securities
$5,224K
Purchases of property and
equipment
$9K
Buy us a coffee